---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-121811"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2026-03-24T23:59:59+00:00"
generated_at: "2026-05-15T09:14:59.295432+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion reports FY2025 net loss of $61.8M; cash runway into Q1 2027; initiates Phase II trials in diabetes

## Summary
- Net loss $61.8M for FY2025 vs $138.4M in FY2024; R&D expenses decreased 47% to $62.0M.
- Cash and equivalents $56.2M as of Dec 31, 2025; projected cash runway into Q1 2027.
- Initiated Phase II trials COVALENT-211 and COVALENT-212 for icovamenib in type 2 diabetes; topline data expected Q4 2026.
- Phase I trial GLP-131 (BMF-650) for obesity initiated; initial 28-day weight reduction data expected Q2 2026.
- Positive 52-week data from COVALENT-111: 1.2% mean HbA1c reduction maintained 9 months off therapy.

## SEC filing metadata
- accession: 0001193125-26-121811
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2026-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000119312526121811/0001193125-26-121811-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000119312526121811/bmea-20260324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-121811
- JSON: https://secwatch.observer/filing/0001193125-26-121811.json
- Plain text: https://secwatch.observer/filing/0001193125-26-121811.txt

## Key facts
- Earnings Releases
  Biomea Fusion, Inc. reported the year ended December 31, 2024 results: net income net loss of $138.4 million.
  - Period: the year ended December 31, 2024
  - Net income: net loss of $138.4 million
  - Result: reported results
  source text: The Company reported a net loss attributable to common stockholders of $61.8 million for the year ended December 31, 2025, which included $9.5 million of stock-based compensation, compared to a net loss of $138.4 million for the same period in 2024, which included $19.1 million of stock-based compensation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840439/000119312526121811/0001193125-26-121811-index.htm
- Earnings Releases
  Biomea Fusion, Inc. reported the full year ended December 31, 2025 results: net income net loss of $61.8 million.
  - Period: the full year ended December 31, 2025
  - Net income: net loss of $61.8 million
  - Result: reported results
  source text: Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the full year ended December 31, 2025 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840439/000119312526121811/0001193125-26-121811-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.